The effects of chlorhexidine, povidone-iodine and vancomycin on growth and biofilms of pathogens that cause prosthetic joint infections: an in-vitro model

IF 3.9 3区 医学 Q1 INFECTIOUS DISEASES
{"title":"The effects of chlorhexidine, povidone-iodine and vancomycin on growth and biofilms of pathogens that cause prosthetic joint infections: an in-vitro model","authors":"","doi":"10.1016/j.jhin.2024.06.010","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p>Chlorhexidine gluconate (CHG) and povidone-iodine (PI) are commonly used to prevent prosthetic joint infection (PJI) during total joint replacement; however, their effective concentrations and impact on biofilms are not well defined.</p></div><div><h3>Aim</h3><p>To determine: (1) the in-vitro minimum inhibitory concentration of CHG and PI against model PJI-causing organisms and clinical isolates; (2) their impact on biofilm formation; (3) whether there is a synergistic benefit to combining the two solutions; and (4) whether adding the antibiotic vancomycin impacts antiseptic activity.</p></div><div><h3>Methods</h3><p>We measured in-vitro growth and biofilm formation of <em>Staphylococcus epidermidis</em>, meticillin-sensitive and meticillin-resistant <em>Staphylococcus aureus</em>, <em>Escherichia coli</em>, <em>Pseudomonas aeruginosa</em> and <em>Candida albicans</em>, as well as recent clinical isolates, in the presence of increasing concentrations of CHG and/or PI. Checkerboard assays were used to measure potential synergy of the solutions together and with vancomycin.</p></div><div><h3>Findings</h3><p>CHG and PI inhibited growth and biofilm formation of all model organisms tested at concentrations of 0.0004% and 0.33% or lower, respectively; highly dilute concentrations paradoxically increased biofilm formation. The solutions did not synergize with one another and acted independently of vancomycin.</p></div><div><h3>Conclusion</h3><p>CHG and PI are effective at lower concentrations than typically used, establishing baselines to support further clinical trials aimed at optimizing wound disinfection. There is no synergistic advantage to using both in combination. Vancomycin is effective at inhibiting the growth of <em>S. epidermidis</em> and <em>S. aureus</em>; however, it stimulates <em>P. aeruginosa</em> biofilm production, suggesting in the rare case of <em>P. aeruginosa</em> PJI, it could exacerbate infection.</p></div>","PeriodicalId":54806,"journal":{"name":"Journal of Hospital Infection","volume":null,"pages":null},"PeriodicalIF":3.9000,"publicationDate":"2024-07-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0195670124002305/pdfft?md5=5542356cda3ead233d61b918b3165481&pid=1-s2.0-S0195670124002305-main.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Hospital Infection","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0195670124002305","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
引用次数: 0

Abstract

Background

Chlorhexidine gluconate (CHG) and povidone-iodine (PI) are commonly used to prevent prosthetic joint infection (PJI) during total joint replacement; however, their effective concentrations and impact on biofilms are not well defined.

Aim

To determine: (1) the in-vitro minimum inhibitory concentration of CHG and PI against model PJI-causing organisms and clinical isolates; (2) their impact on biofilm formation; (3) whether there is a synergistic benefit to combining the two solutions; and (4) whether adding the antibiotic vancomycin impacts antiseptic activity.

Methods

We measured in-vitro growth and biofilm formation of Staphylococcus epidermidis, meticillin-sensitive and meticillin-resistant Staphylococcus aureus, Escherichia coli, Pseudomonas aeruginosa and Candida albicans, as well as recent clinical isolates, in the presence of increasing concentrations of CHG and/or PI. Checkerboard assays were used to measure potential synergy of the solutions together and with vancomycin.

Findings

CHG and PI inhibited growth and biofilm formation of all model organisms tested at concentrations of 0.0004% and 0.33% or lower, respectively; highly dilute concentrations paradoxically increased biofilm formation. The solutions did not synergize with one another and acted independently of vancomycin.

Conclusion

CHG and PI are effective at lower concentrations than typically used, establishing baselines to support further clinical trials aimed at optimizing wound disinfection. There is no synergistic advantage to using both in combination. Vancomycin is effective at inhibiting the growth of S. epidermidis and S. aureus; however, it stimulates P. aeruginosa biofilm production, suggesting in the rare case of P. aeruginosa PJI, it could exacerbate infection.

洗必泰、聚维酮碘和万古霉素对引起人工关节感染的病原体的生长和生物膜的影响:体外模型。
背景:葡萄糖酸氯己定(CHG)和聚维酮碘(PI)常用于预防全关节置换术中的假体关节感染(PJI);然而,它们的有效浓度及其对生物膜的影响尚未明确。目的:确定:(1) CHG 和 PI 对模型 PJI 致病菌和临床分离菌的体外最小抑制浓度;(2) 它们对生物膜形成的影响;(3) 将两种溶液结合使用是否有协同作用;(4) 加入抗生素万古霉素是否会影响杀菌活性:我们测量了表皮葡萄球菌、对甲氧西林敏感和耐甲氧西林金黄色葡萄球菌、大肠埃希菌、铜绿假单胞菌和白色念珠菌以及最近的临床分离物在浓度不断增加的 CHG 和/或 PI 存在下的体外生长和生物膜形成情况。采用棋盘试验来衡量这两种溶液与万古霉素的潜在协同作用:结果:CHG 和 PI 在浓度分别为 0.0004% 和 0.33% 或更低时,可抑制所有受试模式生物的生长和生物膜的形成;高浓度稀释液反而会增加生物膜的形成。这两种溶液不会相互增效,其作用独立于万古霉素:结论:CHG 和 PI 在较低浓度时比通常使用的浓度更有效,这为进一步临床试验优化伤口消毒提供了基础。两者联合使用没有协同优势。万古霉素能有效抑制表皮葡萄球菌和金黄色葡萄球菌的生长;但它会刺激铜绿假单胞菌生物膜的生成,这表明在铜绿假单胞菌PJI的罕见病例中,万古霉素可能会加重感染。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Journal of Hospital Infection
Journal of Hospital Infection 医学-传染病学
CiteScore
12.70
自引率
5.80%
发文量
271
审稿时长
19 days
期刊介绍: The Journal of Hospital Infection is the editorially independent scientific publication of the Healthcare Infection Society. The aim of the Journal is to publish high quality research and information relating to infection prevention and control that is relevant to an international audience. The Journal welcomes submissions that relate to all aspects of infection prevention and control in healthcare settings. This includes submissions that: provide new insight into the epidemiology, surveillance, or prevention and control of healthcare-associated infections and antimicrobial resistance in healthcare settings; provide new insight into cleaning, disinfection and decontamination; provide new insight into the design of healthcare premises; describe novel aspects of outbreaks of infection; throw light on techniques for effective antimicrobial stewardship; describe novel techniques (laboratory-based or point of care) for the detection of infection or antimicrobial resistance in the healthcare setting, particularly if these can be used to facilitate infection prevention and control; improve understanding of the motivations of safe healthcare behaviour, or describe techniques for achieving behavioural and cultural change; improve understanding of the use of IT systems in infection surveillance and prevention and control.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信